Dr. Kimberly Akemi Dequattro, MD, MM

Dr. Dequattro practices at Stanford Hospital at 300 Pasteur Drive in Stanford, California, part of Stanford University.

Dr. Dequattro's NPI, 1295096873, was assigned on May 31, 2012. Dr. Dequattro graduated from University of Southern California Keck School of Medicine in 2012. Dr. Dequattro holds Pennsylvania license MD474947.

Dr. Dequattro's primary practice is Stanford Hospital at 300 Pasteur Drive, at 300 Pasteur Drive, Stanford, CA 94305 in Santa Clara County. The practice phone is (650) 723-4000.

Dr. Dequattro's primary practice is Stanford Hospital at 300 Pasteur Drive in Stanford, California, part of Stanford University. The medical group on file is Penn Medicine Lancaster General Health. Dmand AI also links Dr. Dequattro to 1 more hospital and 2 medical groups, each named with a free account. Dr. Dequattro's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Dequattro practices, 2 sites in all. Vendor and product names are available with a free account.

Rheumatology is Dr. Dequattro's primary specialty in the NPI Registry, under taxonomy code 207RR0500X. Dr. Dequattro is licensed in Pennsylvania.

CMS data shows 225 Medicare services from Dr. Dequattro across 4 procedure codes in 2024, for 95 Medicare patients. Medicare paid $13,386 for them.

CMS counts 95 Medicare patients who saw Dr. Dequattro in 2024. The largest group is 65 to 74, with 45 patients. 71% of them have high blood pressure, and 68% have arthritis. 25% are also on Medicaid. Their average risk score is 2.00, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Dequattro's median patient age at 47, with 71% women.

In 2024, Dr. Dequattro wrote 656 Medicare Part D claims for 111 patients. 79% of them were for generic drugs. CMS names the drug for 473 of them, across 17 drugs with 11 or more claims each, at $264,549 in total drug cost. In 2023, CMS named 443 claims across 15 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 85 out of 100 for Dr. Dequattro for performance year 2024, reported as part of a group. Dr. Dequattro accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Dequattro as offering telehealth.

Dmand AI links 20 papers to Dr. Dequattro, published from 2017 to 2025. 2022 was the busiest year, with 4. The most frequent topics are Lupus Erythematosus, Systemic, Patient Reported Outcome Measures and Rheumatic Diseases. Dr. Dequattro has published most often in Arthritis Care Res (Hoboken). Dr. Dequattro's most frequent co-authors are Cristina M. Lanata, MD, Jinoos Yazdany, MD and Christie M. Bartels, MD.

CMS Open Payments shows 7 general payments to Dr. Dequattro from 2 drug and device companies from 2024 to 2025. Consulting fees make up the largest share, 90% of the total. Genentech, Inc. paid the most, $5,776.

Dr. Dequattro graduated from University of Southern California Keck School of Medicine in 2012.